Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFORD: OMEGA-3 in Atrial Fibrillation
NCT01235130Phase 3Completed
- Sponsor
- Montréal Heart Institute
- Start
- Mar 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omega-3 fatty acid in Atrial fibrillation (AFib) (2 arms), sponsored by Montréal Heart Institute. Primary endpoint: Time to first relapse of atrial fibrillation. Started Mar 2009; status: completed.
02
Drugs
omega-3 fatty acid
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01235130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01235130.